Nelarabine-Induced Myelotoxicity

Neurology. 2021 Jan 26;96(4):175-176. doi: 10.1212/WNL.0000000000011343. Epub 2020 Dec 11.

Authors

Ajay A Madhavan¹, Carrie M Carr¹, Hassan Alkhateeb¹, Nathan P Staff¹, Elie Naddaf²

Affiliations

¹ From the Departments of Radiology (A.A.M., C.M.C.), Hematology and Oncology (H.A.), and Neurology (N.P.S., E.N.), Mayo Clinic, Rochester, MN.
² From the Departments of Radiology (A.A.M., C.M.C.), Hematology and Oncology (H.A.), and Neurology (N.P.S., E.N.), Mayo Clinic, Rochester, MN. naddaf.elie@mayo.edu.

PMID: 33310877
DOI: 10.1212/WNL.0000000000011343

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Arabinonucleosides / adverse effects*
Ataxia / chemically induced*
Ataxia / diagnostic imaging*
Female
Humans
Muscle Weakness / chemically induced*
Muscle Weakness / diagnostic imaging*

Substances

Arabinonucleosides
nelarabine